March 18, 2009 03:18 PM Eastern Daylight Time
BRANFORD, Conn. & TORONTO—(BUSINESS WIRE)—Don Very, Ph.D., Vice President, Research of IBA today announced that IBA’s Assay Development Laboratory is now offering customers enhanced assay development services with the recent acquisition of a dotLab® System – an enabling platform for the development and deployment of assays. “Partnering with IBA is a logical next step for Axela as we continue to expand the breadth and depth of products that add value to researchers conducting protein discovery and clinical diagnostic research,” commented Rocky Ganske, President and CEO of Axela Inc.
“Partnering with IBA is a logical next step for Axela as we continue to expand the breadth and depth of products that add value to researchers conducting protein discovery and clinical diagnostic research”
dotLab System customers in the pharmaceutical, biotech and diagnostic industries can now augment internal biomarker programs with IBA’s contract assay development expertise for single or multiplexed immunoassay development.
In addition to custom assay development, IBA is partnering with Axela to expand the menu of biomarker assays optimized for use with the dotLab platform and the soon to be available panelPlusTM Sensors. Axela’s new real-time sensor technology offers customers freedom to combine preconfigured assays with their novel markers to accelerate biomarker validation.
The dotLab System’s novel technology for performing immunoassays and real-time study of protein interactions has demonstrated enhanced performance in many application areas including cardiology, oncology, and infectious disease. Benefits include extended dynamic range, simultaneous measurement of high and low abundance markers and concurrent detection of secondary information such as binding partners, isotype and avidity.
IBA is pleased to announce the launch of its ImmunoBead Array™ Mouse Biomarker Panel and sample analysis service. Utilizing the xMAP® technology developed by the Luminex Corporation, IBA has developed six multiplexed panels of biomarkers associated with diabetes, obesity, metabolism, and inflammation. The performance of each of the panels has been validated for the analysis of mouse plasma samples. These comprehensive panels offer a quantitative, data-rich approach to plasma sample analysis and are a cost-effective means to acquire valuable biomarker information while conserving time, reagents, and sample volume.